{"id":"triptorelin-pamoate-15mg","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Hot flashes"},{"rate":"10-20","effect":"Injection site reactions"},{"rate":"40-60","effect":"Decreased libido"},{"rate":"30-50","effect":"Erectile dysfunction"},{"rate":"10-20","effect":"Headache"},{"rate":"10-20","effect":"Fatigue"},{"rate":"5-15","effect":"Gynecomastia"},{"rate":"variable","effect":"Transient increase in testosterone (flare)"}]},"_chembl":{"chemblId":"CHEMBL1200554","moleculeType":"Protein","molecularWeight":"1699.85"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Triptorelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) that binds to GnRH receptors in the pituitary gland. Initial stimulation of GnRH receptors is followed by desensitization and downregulation, resulting in sustained suppression of gonadotropin secretion and consequent reduction in testosterone (in males) or estrogen (in females). This hormonal suppression is used therapeutically in hormone-dependent conditions.","oneSentence":"Triptorelin pamoate is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased sex hormone production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:14:42.285Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced prostate cancer"},{"name":"Hormone-responsive breast cancer"},{"name":"Endometriosis"},{"name":"Uterine fibroids"},{"name":"Precocious puberty"}]},"trialDetails":[{"nctId":"NCT04736602","phase":"PHASE3","title":"Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.","status":"COMPLETED","sponsor":"Ipsen","startDate":"2021-03-27","conditions":"Central Precocious Puberty","enrollment":32},{"nctId":"NCT06487143","phase":"PHASE4","title":"Efficacy, Metabolism and BMD of the 3-month TP Compared to the 1-month TP in ICPP","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-07-01","conditions":"Central Precocious Puberty","enrollment":134},{"nctId":"NCT04869371","phase":"PHASE2","title":"Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer","status":"UNKNOWN","sponsor":"Hongqian Guo","startDate":"2018-12-12","conditions":"Neoadjuvant Therapy \\ High Risk Prostate Cancer \\ Docetaxel","enrollment":75},{"nctId":"NCT03232281","phase":"PHASE3","title":"Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis","status":"COMPLETED","sponsor":"Ipsen","startDate":"2017-07-28","conditions":"Endometriosis","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Triptorelin pamoate（15mg）","genericName":"Triptorelin pamoate（15mg）","companyName":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","companyId":"sun-yat-sen-memorial-hospital-of-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Triptorelin pamoate is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased sex hormone production. Used for Advanced prostate cancer, Hormone-responsive breast cancer, Endometriosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}